Salivary Gland Cancers: Biology and Systemic Therapy

Area of Science:

• Oncology
• Molecular Biology
• Pathology

Background:

• Salivary gland tumors are rare, heterogeneous, and lack definitive treatment protocols due to limited clinical data.
• Systemic chemotherapy has historically yielded poor patient outcomes.
• Advances in molecular technology enable identification of specific genetic alterations and biomarkers for targeted therapies.

Purpose of the Study:

• To review the current landscape of salivary gland tumor treatment.
• To explore the potential of molecular targets and biomarkers in guiding therapy.
• To highlight the need for improved clinical studies in managing these tumors.

Main Methods:

• Review of existing literature on salivary gland tumors.
• Analysis of molecular alterations, including genetic translocations.
• Evaluation of outcomes from clinical trials involving targeted agents, such as epidermal growth factor receptor (EGFR) inhibitors.

Main Results:

• The CRTC1-MAML2 gene translocation [t(11;19)(q21;p13)] is associated with improved survival in mucoepidermoid carcinomas and potential sensitivity to EGFR inhibition.
• Phase II trials of EGFR inhibitors and other targeted agents have shown limited efficacy, with disease stabilization but no objective responses.

Conclusions:

• Specific genetic alterations like the CRTC1-MAML2 translocation may serve as prognostic markers.
• Targeted therapies, including EGFR inhibitors, have not yet translated into significant clinical benefits for salivary gland tumors.
• Well-designed prospective clinical studies are crucial for advancing the management of salivary gland tumors.